


Responding to Challenges of the Ongoing COVID-19 Pandemic



The health and safety of our colleagues and their families, and maintaining business operations for the patients who rely on us, were our highest priorities in 2021, as the COVID-19 pandemic persisted, spreading through new variants around the world. The pandemic has been called the “inequality virus” as it has hit countries and communities very differently, and both the direct and indirect impacts vary worldwide. As a global healthcare company, we both operate in and serve patients in a variety of circumstances, and our teams closely track developments so we can respond appropriately.

We have taken extra precautions to protect site personnel and operations, including implementing social distancing measures, daily health assessments and split shifts where feasible. We offer a wide range of benefits and programs that are locally customized to meet the unique needs of employees, and regularly offer advice and support to those working from home.



“Our teams did an exceptional job managing the uncertainty of the pandemic to protect the health and safety of our workforce and ensure supply continuity for patients. During 2021, we maintained a global service level of more than 90%. We will remain dedicated to this commitment as long as the pandemic and global unrest endures.”


— **Sinead Griffiths**
Head of Global Supply Chain, Viatriis

In addition to supporting our employees, it has been vital that we continue to provide essential medicines that patients depend on through our reliable business operations. COVID-19 has led to unprecedented disruptions to international trade and transit, and 2021 saw continued activity by governments seeking greater supply security. Amid this challenging backdrop, we upheld high customer service levels via a reliable supply chain to serve patients around the world.

Thanks to efforts to build our supply chain systems and enhance our visibility into patient needs, before the pandemic began, Viatris was well positioned to monitor and respond to the volatility caused by COVID-19. We had established solid processes and systems that were essential to enabling us to focus on getting products to patients. Because of strong relationships with our logistic suppliers and our global and diverse supply chain, we were able to pinpoint specific low stock levels across the network and prioritize what was most important on a daily basis. We were able to move product from one region to another, chartering our own aircraft when other airlines were grounded and getting medicines to patients with vital needs. No single country or company can meet the needs of all patients; but urgent solutions were identified through multi-stakeholder collaborations, and we believe with lasting positive impact.

OUR RESPONSE IN INDIA

India experienced a significant surge of COVID-19 in 2021, with hospitals overrun and patients struggling to gain access to oxygen and life-saving medicines. Across all of our facilities in India, we offered regular training and communication to employees about the pandemic, workplace protective practices and return-to-workplace safety. We encouraged employees to get vaccinated, with vaccination camps organized across our locations for both employees and their families. In all, about 98% of Viatris India employees are vaccinated, which is one of the highest vaccination rates among companies in the country and well above the national average.



We provided health and safety support for all employees, including team members and their families who contracted the virus. Support included access to on-call doctors 24/7, professional counseling, quarantine care and advisory services and home isolation kits.

For those employees who were hospitalized, we worked to ensure our colleagues and their families had access to hospital beds, ventilators, oxygen and medicines. Viatris medical personnel also obtained status updates from hospital personnel, typically on a daily basis. We provided financial and educational support for the families of colleagues lost to COVID-19.

All of these efforts — including our work to ensure business continuity and support employees worldwide — were overseen by a core COVID-19 management team.

As in other parts of the world, mental health was also a big part of our employee outreach efforts in India. An Employee Wellbeing and Assistance Program (EWAP) was launched in several languages in 2021, providing professional counseling to employees and their families. We gave sessions and webinars on positive mental health and provided special health insurance coverage over and above the standard for employees, spouses and children.



“Our ability to help serve patients during the pandemic was dependent on the amazing efforts of our colleagues who continued to work in manufacturing facilities worldwide despite the challenges posed by COVID-19. Making sure that those colleagues and their families were protected was and continues to be a priority for us.”

— **Peter McCormick**
Global Head of Oral Solid Dose and Dermatologics Science & Operations, Viatris

Expanding Access to Remdesivir

We worked closely with the government of India to ensure equitable access of medicines across both state and private hospitals across the country. One of those key medicines was the antiretroviral remdesivir. Viatris teams worked tirelessly to ensure a stable supply of access to remdesivir, under the brand name DESREM™, in India and over 24 other licensed markets to more than 1 million people. A few examples follow:

- Employing a multifaceted approach to quickly increase production of remdesivir, Viatris’ Operations team expanded internal facility capacity while simultaneously onboarding contract manufacturers to increase production.
- Commercial and Operations teams worked with multiple vendors to expedite procurement of raw materials, collaborating with India’s Ministry of External Affairs to expedite delivery timelines from suppliers located outside of the country.
- The Supply Chain team worked with logistic service providers and airline carriers to ensure smooth and timely shipments to all corners of the country.

In addition, we set up a COVID-19 helpline, where Viatris provided information about the availability of remdesivir to patients and healthcare providers. The team worked around the clock to respond to hundreds of daily requests.

In May 2021, our partnership with the government in India also gave us visibility into the growing onset of mucormycosis, a fungal infection that was beginning to occur in patients who had recovered from COVID-19 and had the potential of evolving into a huge crisis across the country.

Foreseeing the urgent need of liposomal amphotericin-B to treat the rapidly rising cases, Viatris leveraged its partnership with Gilead to secure a supply for AmBisome®. Through its collaboration with Gilead, Viatris was able to supply more than 600,000 vials in the months of May and June alone.

We also engaged with on-the-ground efforts in support of local communities through our long-standing corporate social responsibility (CSR) program in India. This included providing ventilators to hospitals, establishing vaccination camps, providing COVID-19 self-test kits and supporting the creation of a modular hospital. Our teams even converted nitrogen generation capabilities at one of our API facilities to produce oxygen for a hospital in Vizag.



“During the most challenging time, our teams in India and around the world worked to take care of each other and patients by ensuring continuity of supply. To be able to accomplish this in the midst of a pandemic shows just how strongly we are driven by our mission.”

— **Rakesh Bamzai**
President - India, Emerging Asia and Access Markets, Viatris

Worldwide, we worked through our established partner networks, including Direct Relief and Americares, to provide funding for needed equipment and supplies. For those Viatris employees outside of India who wanted to help, we partnered with the Red Cross to set up an online portal where colleagues could donate to international COVID-19 relief efforts, which included a significant focus on not only in India but also countries in need including Brazil. Viatris matched employee donations.

FINDING SOLUTIONS THROUGH COLLABORATIONS

The pandemic has amplified inequalities in healthcare systems worldwide, adding increased urgency to build more sustainable systems. Patients in lower-income countries and settings have been hit especially hard, due to the high risk of exposure to COVID-19, limited vaccination rates, impacts on access to all other healthcare and the economic crisis that has followed the pandemic. As part of coming back from the pandemic, we must capture the unique opportunities for cross-sector collaboration and find innovative solutions that work at local, regional and global levels for patients and healthcare systems. Against the backdrop of ongoing efforts to provide the best care possible for today’s patients, governments worldwide are considering how best to prevent future pandemics, while also preparing to respond to the inevitability that COVID-19 will not be the last major health crisis the world faces together.

In 2022, the Medicines Patent Pool announced that Viatris was one of the companies that had signed licensing agreements with originator companies to produce their COVID-19 medicines and supply treatments in more than 90 low- and middle-income countries.¹

Whether ensuring smooth cross-border flows of medicines, convening new cross-sector groups to nimbly tackle demand surges of critical medicines, or lending expertise in the development of policies impacting supply, Viatris has been an active partner to governments around the world in finding solutions that put patients first. In 2021, those efforts included, among many others:

- Witnessing the surge in demand for intensive care medicines, we partnered with Medicines for Europe on a project to assess the need and increase the supply from manufacturers accordingly. The project was endorsed by the European Commission, providing a targeted solution to demand surges during multiple pandemic waves.
- In Australia, Viatris participated in a government/industry advisory panel to the Minister for Health on policy reforms needed to ensure ongoing supply of medicines to patients, such as capping dispensed amounts on individual prescriptions.
- In Japan, we provided, at no cost, 10,000 units of the emergency supportive anaphylaxis treatment drug EpiPen® to more than 1,700 local governments in charge of COVID-19 vaccination programs for use in the event of post-vaccination anaphylaxis. Further, we led educational webinars with more than 20,000 healthcare workers on the administration of EpiPen.
- In Thailand, we worked closely with the Ministries of Health to ensure scientific awareness about medications commonly used to treat severe symptoms of COVID-19 and secure supply in collaboration with authorities.

Understanding the Patient Journey

We continued our partnership with Carenity, a global digital community supporting patients and caregivers, to measure the impact of the COVID-19 pandemic on people living with noncommunicable diseases (NCDs). The findings from more than 4,800 patients interviewed across seven countries in Europe and the U.S. were published in the International Journal of Environmental Research and Public Health.²

- As many as 50% of patients surveyed with NCDs like cardiovascular diseases, mental health conditions, cancers, chronic respiratory diseases and diabetes experienced a worsening of their condition because of disruptions to prevention and treatment services caused by the pandemic
- 17% of respondents developed a new disease
- 26% reported the pandemic impacted regular/long-term treatment intake
- 54% of the patients felt very or completely socially isolated and reported a strong impact of the COVID-19 pandemic on their stress level and state of mind, with higher levels observed in the U.S. compared to Europe
- 59% of the respondents wished to have received additional information regarding the risks associated with their medical condition during the pandemic



Sources

¹[Medicines Patent Pool press release](#)


²[Impact of the COVID-19 Pandemic on Patients Affected by Non-Communicable Diseases in Europe and in the USA](#)

Our work to fight COVID-19 also included going directly into communities with partners to raise awareness of growing mental health issues, creating access to treatments in vulnerable regions and seeking insight into how COVID-19 was affecting care. A few examples are below:

- We launched various mental health initiatives, leveraging the Yellow September campaign, and Towards Life #yougotthis in Brazil, Central America and the Caribbean to reinforce the importance of taking care of mental health, especially during the pandemic. The #yougotthis campaign reached 8 million people in 14 markets.
- In Brazil, Viatris launched The Mental Health Guide with the hospital Oswaldo Cruz. Each chapter was written by a different specialist and the guide was made available for download for healthcare professionals, patients and their families.
- We engaged with hospital groups and the South African Health Products Regulatory Authority to make remdesivir available for the treatment of more than 2,000 hospitalized COVID-19 patients.
- Viatris Vietnam supported Vingroup, a local distribution partner, in their donation of remdesivir to the Ministry of Health to provide expedited and affordable access to patients.
- In France, we partnered with MesDocteurs to announce the launch of an application to help pharmacists manage their appointments with patients seeking the COVID-19 vaccine.
- In Thailand, we worked to raise awareness about long-term lung function issues for some patients who recover from COVID-19. We worked in partnership on the Save Lungs, Save Lives project with the department of disease control (MoPh), Central Chest Institute of Thailand, Bamrasnaradura Infectious Diseases Institute and Physical Therapy Association of Thailand.

A SPECIAL FOCUS ON CHILDREN AND MENTAL HEALTH

Recognizing the need to address the mental health effects of the virus, we worked to help address COVID-19's impact on one of the world's most vulnerable populations: children. Made possible by Viatris, Sesame Workshop published online resources to help families talk about the stigma associated with COVID-19 and encourage kids and grown-ups alike to show empathy, kindness and compassion. In the "Caring for Each Other" series, videos and printable resources aimed to help children manage strong emotions and big feelings or stay connected with family and friends, among other supports.



Our partnership with Sesame Workshop is continuing in 2022, with the release of live action videos addressing topics including separation anxiety and isolation, normalizing seeking help for mental health care and coping with unpredictability and stress. The materials will be available in multiple languages, including English, Arabic, Hindi, Turkish and Korean.